Regeneron Pharmaceuticals Earnings Preview: Can This Streak Continue?

Regeneron Pharmaceuticals (NASDAQ:REGN) will report earnings before markets open on Friday, May 3rd. Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.

Here is your Cheat Sheet to Regeneron Pharmaceuticals Earnings:

Earnings Expectations: Analysts expect earnings of $0.95 per share on revenues of $424.26 million. Currently, the company’s P/E ratio stands at 31.90.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $1.27 to a profit $1.05. For the current year, the average estimate is a profit of $4.4, which is worse than the estimate ninety days ago.

The stock market is at 5-year highs! Discover the best stocks to buy in today’s market. CLICK HERE for Your Stock Investor Cheat Sheet NOW!

Earnings Trends:

Here’s how Regeneron Pharmaceuticals has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 238.46 379.27 459.07 445.82 1,378
Diluted EPS ($) -1.00 -0.85 -1.26 -2.45 6.75

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 122.98 231.79 304.40 427.69 414.60
Diluted EPS ($) -0.5822 0.11 0.70 1.72 3.559

Past Performance:
Regeneron Pharmaceuticals has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]